Claritev Corporation (CTEV)
(Delayed Data from NYSE)
$51.14 USD
+11.62 (29.40%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $51.14 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CTEV 51.14 +11.62(29.40%)
Will CTEV be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CTEV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CTEV
Claritev Corporation (CTEV) Q2 Earnings and Revenues Surpass Estimates
New Strong Sell Stocks for July 23rd
CTEV: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Sell Stocks for July 16th
Claritev Corporation (CTEV) Reports Q1 Loss, Tops Revenue Estimates
Is American Well (AMWL) Outperforming Other Medical Stocks This Year?
Other News for CTEV
12 Health Care Stocks Moving In Wednesday's Intraday Session
Q2 2025 Claritev Corp Earnings Call Transcript
Claritev Corp Q2 2025 Earnings: Revenue Surpasses Estimates at $241. ...
Claritev Corporation Reports Second Quarter 2025 Results | CTEV Stock News
Claritev beats top-line and bottom-line estimates; updates FY25 outlook